Pharmacosomes: A Potential Alternative to Conventional Vesicular Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmacosomes: A Potential Alternative to Conventional Vesicular Systems
Pharmacosomes can pass through biomembranes efficiently and possess several advantages over traditional vesicular drug-delivery systems.


Pharmaceutical Technology
Volume 33, Issue 6, pp. 62-65

References

1. Y. Jin et al., "Self-Assembled Drug Delivery Systems-Properties and In Vitro In Vivo Behaviour of Acyclovir Self-Assembled Nanoparticles (san)," Int. J. Pharm. 309 (1–2), 199–207 (2006).

2. P. Goyal et al., "Liposomal Drug Delivery Systems: Clinical Applications," Acta Pharm. 55, 1–25 (2005).

3. H.A. Lieberman, M.M. Rieger, and G.S. Banker, Pharmaceutical Dosage Forms: Disperse Systems (Informa Healthcare, London, England, 1998), p. 163.

4. S.S. Biju et al., "Vesicular Systems: An Overview," Ind. Jour. Pharm. Sci. 68 (2), 141–153 (2006).

5. M.O. Vaizoglu and P.P. Speiser, "Pharmacosomes—A Novel Drug Delivery System," Acta Pharm. Suec. 23, 163–172 (1986).

6. A. Singh and R. Jain, "Targeted Vesicular Constructs For Cytoprotection and Treatment of H. Pylori Infections," US Patent 6576,625 (2003).

7. I.P. Kaur and M. Kanwar, "Ocular Preparations: The Formulation Approach," Drug Dev. Ind. Pharm. 28 (5), 473–493 (2002).

8. F. Volkering et al., "Influence of Nonionic Surfactants on Bioavailability and Biodegradation of Polycyclic Aromatic Hydrocarbons," App. Environ. Micro. 61 (5), 1699–1705 (1995).

9. A. Steve, "Lipophilic Drug Derivatives For Use In Liposomes," US Patent 5534499 (1996).

10. I. Taskintuna et al., "Evaluation Of A Novel Lipid Prodrug for Intraocular Drug Delivery: Effect of Acyclovir Diphosphate Dimyristoylglycerol in a Rabbit Model With Herpes Simplex Virus-1 Retinitis," Retin. 17 (1), 57–64, (1997).

11. M. J. Lawrence, "Surfactant Systems: Their Use in Drug Delivery," Chem. Soc. Rev. 23, 417–424 (1994).

12. C.C. Muller-Goymann and H.J. Hamann, "Pharmacosomes : Multilamellar Vesicles Consisting Of Pure Drug," Eur. J. Pharm. Biopharm. 37, 113–117 (1991).

13. J.S. Valentino and N.C. William, Lymphatic Transport of Drugs (CRC Press, Boca Raton, FL, 1992), pp. 205.

14. Z.R. Zhang, J.X. Wang, and J. Lu, "Optimization of the Preparation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine Pharmacosomes Using Central Composite Design," Yao Xue Xue Bao 36 (6), 456–461 (2001).

15. Z.R. Zhang and J.X. Wang, "Study on Brain Targeting 3',5'-dioctanoyl-5-fluoro-2'-Deoxyuridine Pharmacosomes," Yao Xue Xue Bao. 36 (10), 771–776 (2001).

16. A. Ping, Y. Jin, and C. Da-wei, "Preparation and In Vivo Behavior of Didanosine Pharmacosomes in Rats," Chin. J. Pharm. 3, 227–235 (2005).

17. M. Gulati et al., "Lipophilic Drug Derivatives In Liposomes," Int. J. Pharm. 165, 129–168 (1998).

18. N.K. Jain, Advances In Controlled and Novel Drug Delivery ( CBS Publishers, New Delhi, India, 2003), p. 276.

19. S. Mantelli, P. Speiser, and H. Hauser, "Phase Behaviour of a Diglyceride Prodrug: Spontaneous Formation of Unilamellar Vesicles," Chem. Phys. Lipid. 37 (4), 329–343 (1985).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here